Skip to main content

Table 1 Characteristics of HCQ-treated SLE patients

From: Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS—evaluation of whole blood, plasma, and serum as sample matrices

Patient characteristics (n = 26)
Females, n (%)21 (81)
Age years, median (range)49.5 (20–79)
Disease duration years, median (range)10.5 (1–30)
Number of ACR criteria, median (range)5 (4–9)
Number of SLICC criteria, median (range)7 (4–12)
SLICC/ACR damage index, median (range)0 (0–4)
SLEDAI at blood sampling, median (range)2 (0–18)
Creatinine (μmol/L), median (range)70 (41–178)
Alanine aminotransferase (μkat/L), median (range)0.43 (0.16–0.87)
BMIa, median (range)25 (18.4–35.3)
HCQ dose 2800 mg/week, n (%)2 (8)
HCQ dose 1800–2000 mg/week, n (%)9 (35)
HCQ dose 1400 mg/week, n (%)14 (54)
HCQ dose 0 mg/week, n (%)1 (4)
Prednisone dose, mg/day median (range)1.25 (0–25)
Azathioprine, n (%)7 (29)
Mycophenolate mofetil, n (%)2 (8)
Methotrexate, n (%)2 (8)
Intravenous immunoglobulins, n (%)2 (8)
Rituximab, n (%)2 (8)
Belimumab, n (%)1 (4)
No other DMARDs, n (%)11 (42)
  1. aBMI available for 13 out of 26 patients
  2. ACR American College of Rheumatology, SLICC Systemic Lupus International Collaborating Clinics [27, 28], SLEDAI Systemic Lupus Erythematosus Disease Activity Index [29], DMARD disease-modifying antirheumatic drug